News
Zevra Therapeutics Q1 2025 earnings reveal strong MIPLYFFA traction, robust cash infusion from PRV sale, and pipeline progress.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback